Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for inducing T cells for immunocytotherapy from pluripotent stem cells

A technology for pluripotent stem cells and immunotherapy, which is applied in the field of T cells for inducing cellular immunotherapy, and can solve problems such as TCR specific loss

Active Publication Date: 2017-08-18
KYOTO UNIV +1
View PDF41 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This additional TCRα gene rearrangement not only results in a loss of TCR specificity, but may also generate autoreactive T cells due to mispairing with an undesired chain

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for inducing T cells for immunocytotherapy from pluripotent stem cells
  • Method for inducing T cells for immunocytotherapy from pluripotent stem cells
  • Method for inducing T cells for immunocytotherapy from pluripotent stem cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0111] Establishment of iPS cells from T cells with a homozygous HLA haplotype and regeneration of T cells from iPS cells thus obtained.

[0112] Peripheral blood obtained from a donor homozygous for HLA-A*3303-B*4403-C*1403-ERB1*1302 was used.

[0113] 1) Establishment of Homo-T-iPS cells

[0114] The culture medium used is as follows:

[0115] 【Table 1】

[0116] Culture medium for T cells (T cell culture medium)

[0117] quantity final concentration RPMI 45ml human AB serum 5ml 10％ Total 50ml

[0118] A. Activation of CD8-positive T cells

[0119] 1. Use Ficoll to refine peripheral blood mononuclear cells obtained from healthy volunteers, and use MACS beads to enrich CD8-positive cells.

[0120] 2. Disperse the enriched cells in T cell culture medium and add IL-2 (final concentration: 30U / mL), IL-7 (final concentration: 5ng / mL) and IL-15 (final concentration: 1ng / mL ). Dynabeads Human T-Activator CD3 / CD28 was added to form a be...

Embodiment 2

[0169] 1. Induction of CD8 positive T cells from T-iPS cells generated in Example 1.

[0170] 2. Using the iPS cell clones obtained in Example 1 with homozygous HLA haplotypes. Donor A (whose HLA haplotype has at least one match with the HLA haplotype of the iPS cell) and donor B (whose HLA haplotype does not match the HLA haplotype of the iPS cell at all) are selected.

[0171] Donor A: HLA-A*31:01 / 33:03; B*44:03 / 48:01; C*04:01 / 14:03; DRB1*04:03 / 13:02

[0172] Donor B: HLA-A*24:02 / 24:02; B*07:02 / 52:01; C*07:02 / 12:02; DRB1*01:01 / 15:02

[0173] 3. Using Ficoll to purify monocytes from the peripheral blood of donor A and donor B, and enrich CD8 positive cells by CD8 microbeads.

[0174] 4. Perform mixed lymphocyte reaction (MLR) using CD8-positive T cells regenerated from T-iPS cells as a stimulating factor. CD8 cells obtained from donors were used as effectors. Effector cells were fluorescently labeled using the CellTrace Violet Cell Proliferation Kit. Cell Trace CFSF Cell...

Embodiment 3

[0180] The T-iPS cells having a homozygous HLA haplotype obtained in Example 1 were differentiated into CD8-positive T cells (CTL) by conventional methods. It was examined whether CTLs would activate NK cells derived from peripheral blood of subjects with heterozygous HLA haplotypes, one of which matched the HLA haplotype of iPS cells.

[0181] 1. The CD8-positive T cells differentiated from iPS cells with a homozygous HLA haplotype by conventional methods in Example 1 were used as stimulators.

[0182] 2. Establish iPS cells from cells of donor A with heterozygous HLA haplotypes (one of which matches the HLA haplotype of the stimulator cell) by conventional methods, and differentiate the resulting iPS cells into CD8 positive T cells. And the obtained CD8 positive T cells were also used as stimulatory factors.

[0183] 3. Obtain peripheral blood from donor A, and use Ficoll to separate peripheral blood mononuclear cells (PBMC). NK cells were enriched from PBMCs by negative ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed is a method for inducing T cells for immunocytotherapy, the method including (1) a step for providing human pluripotent stem cells with a knocked out Rag1 and / or Rag2 gene, the pluripotent stem cells having a desired antigen-specific T cell receptor gene, and (2) a step for inducing T cells from the pluripotent stem cells of step (1). Further disclosed are immunocytotherapy using T cells for immunocytotherapy, and an iPS cell bank for immunocytotherapy.

Description

technical field [0001] The present application relates to a method for inducing T cells for cellular immunotherapy. In particular, a method for efficiently and reliably inducing T cells having a desired antigen-specific T cell receptor gene from pluripotent stem cells such as iPS cells is provided. The present application also relates to a method for forming a cell bank using iPS cells, which can be effectively used for cellular immunotherapy. Background technique [0002] Each T cell expresses T cell receptors (TCRs) with different specificities. When an infectious disease develops, a T cell with the appropriate specificity proliferates to form a T cell population (clone) that fights the pathogen. This is the basic idea of ​​acquired immunity. If it is possible to artificially expand T cells with the desired antigen-specific TCR, the expanded T cells can be used for adoptive immunotherapy. The expansion of specific T cells is called "cloning". In fact, autologous trans...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/10A61K35/17A61P35/00
CPCA61K35/14A61P35/00A61K35/17C12N2506/45C12N2501/515C12N2510/00C12N5/0696C12N5/0638C12N5/0636C07K14/4705C12N5/10
Inventor 金子新河本宏增田乔子南川淳隆堀田秋津岛津裕一濑大志
Owner KYOTO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com